1900
document
The impact of schizophrenic patient functionality on service utilization and cost . Based on a presentation by Sandra L. Tunis , PhD . With the advent of atypical agents in the treatment of schizophrenia , physicians and policy makers must consider the costs that may accompany greater clinical efficacy . Analyses reveal that olanzapine shows a greater clinical cost effectiveness , as well as a greater functional cost effectiveness , than haloperidol , and that functional outcomes , in particular , show promise as important measures of effectiveness . Functional outcomes can help differentiate medications and can be used to help demonstrate the cost effectiveness of atypical agents . Mental health and physical health functioning , as well as work status , are all measures of functioning that have been used to evaluate treatment strategies . When comparing olanzapine with haloperidol , cost savings are seen throughout the treatment period ( 1 year ) , with physical functioning most highly affected over time . Functional outcomes can therefore serve 2 purposes : to enhance compliance by improving health-related quality of life and to assist in making both treatment and formulary decisions .
1901
Intervention_Pharmacological
olanzapine
1902
Intervention_Pharmacological
haloperidol
1903
Intervention_Pharmacological
olanzapine
1904
Intervention_Pharmacological
haloperidol
1905
Outcome_Other
service utilization and cost
1906
Outcome_Other
clinical cost effectiveness
1907
Outcome_Other
functional cost effectiveness
1908
Outcome_Other
cost effectiveness
1909
Outcome_Mental
Mental health
1910
Outcome_Physical
physical health functioning
1911
Outcome_Mental
work status
1912
Outcome_Other
cost savings
1913
Outcome_Physical
physical functioning
1914
Outcome_Other
health-related quality of life
1915
Participant_Condition
schizophrenic